65 related articles for article (PubMed ID: 37991558)
1. Treatment With Liposomal Irinotecan Plus Fluorouracil and Leucovorin for Patients With Previously Treated Metastatic Biliary Tract Cancer: The Phase 2b NIFTY Randomized Clinical Trial.
Hyung J; Kim I; Kim KP; Ryoo BY; Jeong JH; Kang MJ; Cheon J; Kang BW; Ryu H; Lee JS; Kim KW; Abou-Alfa GK; Yoo C
JAMA Oncol; 2023 May; 9(5):692-699. PubMed ID: 36951834
[TBL] [Abstract][Full Text] [Related]
2. The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort.
Su YY; Chiang NJ; Tsai HJ; Yen CJ; Shan YS; Chen LT
Sci Rep; 2020 May; 10(1):7420. PubMed ID: 32366911
[TBL] [Abstract][Full Text] [Related]
3. nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients.
Ueno M; Nakamori S; Sugimori K; Kanai M; Ikeda M; Ozaka M; Furukawa M; Okusaka T; Kawabe K; Furuse J; Komatsu Y; Ishii H; Sato A; Shimizu S; Chugh P; Tang R; Ioka T
Cancer Med; 2020 Dec; 9(24):9396-9408. PubMed ID: 33099898
[TBL] [Abstract][Full Text] [Related]
4. Is There Room for Liposomal Irinotecan in Biliary Tract Cancer? A Meta-analysis of Randomised Trials.
Merz V; Messina C; Zecchetto C; Quinzii A; Frisinghelli M; Trentin C; Salati M; Caffo O; Melisi D
Clin Oncol (R Coll Radiol); 2024 Feb; 36(2):87-97. PubMed ID: 38129199
[TBL] [Abstract][Full Text] [Related]
5. Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial.
Macarulla Mercadé T; Chen LT; Li CP; Siveke JT; Cunningham D; Bodoky G; Blanc JF; Lee KH; Dean A; Belanger B; Wang-Gillam A
Pancreas; 2020 Jan; 49(1):62-75. PubMed ID: 31856081
[TBL] [Abstract][Full Text] [Related]
6. Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer.
Tang CY; Yang SH; Li CP; Su YY; Chiu SC; Bai LY; Shan YS; Chen LT; Chuang SC; Chan DC; Yen CJ; Peng CM; Chiu TJ; Chen YY; Chen JS; Chiang NJ; Chou WC
Pancreatology; 2024 Mar; ():. PubMed ID: 38565467
[TBL] [Abstract][Full Text] [Related]
7. A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy.
Grierson PM; Suresh R; Tan B; Pedersen KS; Amin M; Park H; Trikalinos NA; Liu J; Boice N; Brown A; Bansod S; Wang-Gillam A; Lim KH
Clin Cancer Res; 2023 Dec; 29(23):4733-4739. PubMed ID: 37801295
[TBL] [Abstract][Full Text] [Related]
8. NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC).
Craig Z; Swain J; Batman E; Wadsley J; Reed N; Faluyi O; Cave J; Sharma R; Chau I; Wall L; Lamarca A; Hubner R; Mansoor W; Sarker D; Meyer T; Cairns DA; Howard H; Valle JW; McNamara MG
BMJ Open; 2020 Feb; 10(2):e034527. PubMed ID: 32029495
[TBL] [Abstract][Full Text] [Related]
9. The GIANT trial (ECOG-ACRIN EA2186) methods paper: A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer - defining a new treatment option for older vulnerable patients.
Dotan E; Catalano P; Lenchik L; Boutin R; Yao X; Marques HS; Ioffe D; Zhen DB; Li D; Wagner LI; Simon MA; Wong TZ; O'Dwyer PJ
J Geriatr Oncol; 2023 Apr; 14(3):101474. PubMed ID: 36963200
[TBL] [Abstract][Full Text] [Related]
10. Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan.
Ko AH
Int J Nanomedicine; 2016; 11():1225-35. PubMed ID: 27099488
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of liposomal irinotecan as the second-line treatment for advanced pancreatic cancer: A systematic review and meta-analysis.
Chen BS; Chan SY; Bteich F; Kuang C; Meyerhardt JA; Ma KS
Crit Rev Oncol Hematol; 2024 May; ():104386. PubMed ID: 38735505
[TBL] [Abstract][Full Text] [Related]
12. Liposomal irinotecan in gemcitabine-refractory metastatic pancreatic cancer: efficacy, safety and place in therapy.
Kipps E; Young K; Starling N
Ther Adv Med Oncol; 2017 Mar; 9(3):159-170. PubMed ID: 28344661
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma.
Singhal R; Rogers SC; Lee JH; Ramnaraign B; Sahin I; Fabregas JC; Thomas RM; Hughes SJ; Nassour I; Hitchcock K; Russell K; Kayaleh O; Turk A; Zlotecki R; DeRemer DL; George TJ
Future Oncol; 2023 Sep; 19(27):1841-1851. PubMed ID: 37753702
[TBL] [Abstract][Full Text] [Related]
14. Risk Factors for Adverse Events of Nanoliposomal Irinotecan Plus 5-Fluorouracil and L-leucovorin.
Ito T; Suno M; Egawa H; Hiraoka S; Kamei K; Sano S; Ashida R; Kawai M; Matsubara K
Cancer Diagn Progn; 2024; 4(3):244-249. PubMed ID: 38707740
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of first-line chemotherapies for patients with advanced pancreatic ductal adenocarcinoma: A systematic review and network meta-analysis.
Kang MJ; Li HX; Gan Y; Fang C; Yang XL; Li B; Su S
Heliyon; 2024 Apr; 10(8):e27679. PubMed ID: 38681566
[TBL] [Abstract][Full Text] [Related]
16. Integration of liposomal irinotecan in the first-line treatment of metastatic pancreatic cancer: try to do not think about the white bear.
Melisi D; Casalino S; Pietrobono S; Quinzii A; Zecchetto C; Merz V
Ther Adv Med Oncol; 2024; 16():17588359241234487. PubMed ID: 38584763
[TBL] [Abstract][Full Text] [Related]
17. Liposomal irinotecan plus fluorouracil/leucovorin in older patients with advanced pancreatic cancer: a single-center retrospective study.
Nagashima S; Kobayashi S; Tsunoda S; Yamachika Y; Tozuka Y; Fukushima T; Morimoto M; Ueno M; Furuse J; Maeda S
Int J Clin Oncol; 2024 Feb; 29(2):188-194. PubMed ID: 37991558
[TBL] [Abstract][Full Text] [Related]
18. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
[TBL] [Abstract][Full Text] [Related]
19. Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study.
Bang YJ; Li CP; Lee KH; Chiu CF; Park JO; Shan YS; Kim JS; Chen JS; Shim HJ; Rau KM; Choi HJ; Oh DY; Belanger B; Chen LT
Cancer Sci; 2020 Feb; 111(2):513-527. PubMed ID: 31789476
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]